162 related articles for article (PubMed ID: 16219326)
21. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
Varani K; Rizzi A; Calo G; Bigoni R; Toth G; Guerrini R; Gessi S; Salvadori S; Borea PA; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):270-7. PubMed ID: 10543428
[TBL] [Abstract][Full Text] [Related]
23. Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation.
Evans RM; You H; Hameed S; Altier C; Mezghrani A; Bourinet E; Zamponi GW
J Biol Chem; 2010 Jan; 285(2):1032-40. PubMed ID: 19887453
[TBL] [Abstract][Full Text] [Related]
24. Two C-terminal amino acids, Ser(334) and Ser(335), are required for homologous desensitization and agonist-induced phosphorylation of opioid receptor-like 1 receptors.
Wang HL; Kuo YL; Hsu CY; Huang PC; Li AH; Chou AH; Yeh TH; Chen YL
Cell Signal; 2006 May; 18(5):670-8. PubMed ID: 16019191
[TBL] [Abstract][Full Text] [Related]
25. Pertussis toxin-insensitive signaling of the ORL1 receptor: coupling to Gz and G16 proteins.
Chan JS; Yung LY; Lee JW; Wu YL; Pei G; Wong YH
J Neurochem; 1998 Nov; 71(5):2203-10. PubMed ID: 9798948
[TBL] [Abstract][Full Text] [Related]
26. Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.
Narita M; Mizoguchi H; Oji DE; Dun NJ; Hwang BH; Nagase H; Tseng LF
Br J Pharmacol; 1999 Nov; 128(6):1300-6. PubMed ID: 10578145
[TBL] [Abstract][Full Text] [Related]
27. The regulators of G protein signaling (RGS) domains of RGS4, RGS10, and GAIP retain GTPase activating protein activity in vitro.
Popov S; Yu K; Kozasa T; Wilkie TM
Proc Natl Acad Sci U S A; 1997 Jul; 94(14):7216-20. PubMed ID: 9207071
[TBL] [Abstract][Full Text] [Related]
28. Spatial regulation of Galphai protein signaling in clathrin-coated membrane microdomains containing GAIP.
Elenko E; Fischer T; Niesman I; Harding T; McQuistan T; Von Zastrow M; Farquhar MG
Mol Pharmacol; 2003 Jul; 64(1):11-20. PubMed ID: 12815156
[TBL] [Abstract][Full Text] [Related]
29. Presence of opioid receptor-like (ORL1) receptor mRNA splice variants in peripheral sensory and sympathetic neuronal ganglia.
Xie GX; Meuser T; Pietruck C; Sharma M; Palmer PP
Life Sci; 1999; 64(22):2029-37. PubMed ID: 10374928
[TBL] [Abstract][Full Text] [Related]
30. Induction of G protein-coupled receptor kinases 2 and 3 contributes to the cross-talk between mu and ORL1 receptors following prolonged agonist exposure.
Thakker DR; Standifer KM
Neuropharmacology; 2002 Nov; 43(6):979-90. PubMed ID: 12423667
[TBL] [Abstract][Full Text] [Related]
31. G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.
Onali P; Olianas MC
Br J Pharmacol; 2004 Nov; 143(5):638-48. PubMed ID: 15451772
[TBL] [Abstract][Full Text] [Related]
32. Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.
Talbot JN; Roman DL; Clark MJ; Roof RA; Tesmer JJ; Neubig RR; Traynor JR
J Neurochem; 2010 Feb; 112(4):1026-34. PubMed ID: 20002516
[TBL] [Abstract][Full Text] [Related]
33. RGS17/RGSZ2 and the RZ/A family of regulators of G-protein signaling.
Nunn C; Mao H; Chidiac P; Albert PR
Semin Cell Dev Biol; 2006 Jun; 17(3):390-9. PubMed ID: 16765607
[TBL] [Abstract][Full Text] [Related]
34. Regulator of G protein signaling 4 confers selectivity to specific G proteins to modulate mu- and delta-opioid receptor signaling.
Leontiadis LJ; Papakonstantinou MP; Georgoussi Z
Cell Signal; 2009 Jul; 21(7):1218-28. PubMed ID: 19324084
[TBL] [Abstract][Full Text] [Related]
35. Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors.
Neal CR; Owens CE; Taylor LP; Hoversten MT; Akil H; Watson SJ
J Chem Neuroanat; 2003 Jul; 25(4):233-47. PubMed ID: 12842269
[TBL] [Abstract][Full Text] [Related]
36. RGS19 enhances cell proliferation through its C-terminal PDZ motif.
Tso PH; Wang Y; Wong SY; Poon LS; Chan AS; Wong YH
Cell Signal; 2010 Nov; 22(11):1700-7. PubMed ID: 20599498
[TBL] [Abstract][Full Text] [Related]
37. RGS proteins: new players in the field of opioid signaling and tolerance mechanisms.
Xie GX; Palmer PP
Anesth Analg; 2005 Apr; 100(4):1034-1042. PubMed ID: 15781518
[TBL] [Abstract][Full Text] [Related]
38. RGS19 converts iron deprivation stress into a growth-inhibitory signal.
Hwang J; Kim HS; Kang BS; Kim DH; Ryoo ZY; Choi SU; Lee S
Biochem Biophys Res Commun; 2015 Aug; 464(1):168-75. PubMed ID: 26116529
[TBL] [Abstract][Full Text] [Related]
39. Capturing of the free cysteine residue in the ligand-binding site by affinity labeling of the ORL1 nociceptin receptor.
Matsushima A; Nishimura H; Inamine S; Uemura S; Shimohigashi Y
Bioorg Med Chem; 2011 Dec; 19(24):7597-602. PubMed ID: 22061823
[TBL] [Abstract][Full Text] [Related]
40. Expression of opioid receptor-like 1 (ORL1) & mu opioid receptors in the spinal cord of morphine tolerant mice.
Ray SB; Gupta YK; Wadhwa S
Indian J Med Res; 2005 Mar; 121(3):194-202. PubMed ID: 15802762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
